Story Stocks^®

Axsome Therapeutics (AXSM) is trading sharply higher after announcing this morning that the FDA accepted for filing its supplemental New Drug Application (sNDA) for AXS-05 in Alzheimer's disease (AD) agitation and granted the application Priority Review. Alongside that, the company said it received formal pre-NDA meeting minutes from the FDA that support an AXS-12 NDA submission for cataplexy in narcolepsy.

• The Priority Review designation tightens the FDA timeline for what could be a meaningful label expansion opportunity for AXS-05 in AD agitation and reflects the FDA's view that, if approved, the therapy may offer significant improvements versus existing options.
• Notably, AXS-05 already has commercial momentum. It is marketed as AUVELITY for major depressive disorder, and Q3 performance was strong with net product sales up 69% yr/yr to $136.1 mln.
• AXS-12 adds another near-term catalyst, but it's not de-risked. FDA pre-NDA minutes indicate AXSM's data package would be sufficient to submit an NDA, which it expects to complete in January 2026; however, the FDA must still review the full filing and could raise issues on completeness, safety, labeling, or manufacturing.
• Both indications address sizable, high-need populations. Management characterizes AD agitation as a substantial market with limited options today, noting agitation is reported in up to 76% of Alzheimer's patients; in narcolepsy, cataplexy is seen in an estimated 70% of patients, reinforcing the relevance of a differentiated treatment option.

Briefing.com Analyst Insight

Today's FDA updates are sending AXSM shares sharply higher because they add visibility into the company's potential 2026 catalysts. The AXS-05 Priority Review puts a clearer timeline around a potentially meaningful label expansion into AD agitation, which management views as a large, high-need market. The AXS-12 pre-NDA minutes add another near-term catalyst by supporting its January NDA filing and reinforcing the idea AXSM could potentially have more marketable central nervous system assets over time. That said, these are still process milestones, not outcomes. Both programs carry substantial regulatory risk and remain subject to full FDA review and approval, but investors are clearly leaning into the potential upside if these milestones translate into approvals.